Biologics Guide for Ankylosing Spondylitis

Table of Contents

  1. Why Biologics Are Different from NSAIDs
  2. When to Start Biologics
  3. The Four Drug Classes in AS
  4. TNF Inhibitors — First-Line Biologics
  5. IL-17 Inhibitors
  6. JAK Inhibitors — Oral Option
  7. IL-23 Inhibitors — Not Effective for AS
  8. Picking Your Biologic — Decision Matrix
  9. Cost and Insurance Reality
  10. How to Give Yourself an Injection
  11. What to Expect — Timeline of Response
  12. Side Effects — What to Watch
  13. Pre-Treatment Screening Checklist
  14. Monitoring During Treatment
  15. Stopping or Switching
  16. Combining Biologics with Other Drugs
  17. Key Research Papers
  18. Research Papers
  19. Connections

1. Why Biologics Are Different from NSAIDs

When your rheumatologist says “we’re going to start a biologic,” they are talking about a fundamentally different class of drug than the NSAIDs you have probably been taking. NSAIDs (ibuprofen, naproxen, celecoxib, indomethacin) manage pain and inflammation by blocking cyclooxygenase enzymes. They help you function. They do not, in any meaningful way, change the long-term course of ankylosing spondylitis.

Biologics block specific cytokines — the molecular messengers driving the disease. In AS these are primarily TNF-alpha, IL-17, and, in the case of JAK inhibitors, the intracellular signaling pathway (JAK-STAT) that many cytokines use to deliver their messages. Turning off these pathways can slow or halt spinal fusion when started early, before syndesmophytes (bony bridges between vertebrae) form.

The trade-off is real. Biologics mean injections or infusions instead of pills. They suppress parts of the immune system. They cost thousands of dollars a month. They involve insurance battles, prior authorizations, specialty pharmacies, and baseline infectious-disease screening. For the right patient — especially a young person with active inflammation — the trade-off is worth it. For someone with mild disease well-controlled on NSAIDs, it usually is not.

Back to Table of Contents

2. When to Start Biologics

The 2019 ACR/SAA/SPARTAN guidelines (American College of Rheumatology / Spondylitis Association of America) recommend moving to a biologic after failing 2 or more NSAIDs at adequate doses for 2–4 weeks each. “Failure” means active disease despite full anti-inflammatory dosing. For the details of what counts as an adequate NSAID trial, see NSAID Strategy.

But there are several situations where rheumatologists push to start a biologic earlier:

If you have any of the above, don’t let a provider keep you on NSAIDs for six months “just to be sure.” Time on inflamed vertebrae is time spent building irreversible fusion.

Back to Table of Contents

3. The Four Drug Classes in AS

Four cytokine/pathway-targeted drug classes are relevant to AS, and only three of them actually work for the axial (spine) disease:

  1. TNF inhibitors (TNFi) — first-line biologic. Block tumor necrosis factor-alpha.
  2. IL-17 inhibitors (IL-17i) — second-line or first-line with specific comorbidities.
  3. JAK inhibitors (JAKi) — oral pills; block intracellular signaling. Reserved for TNFi/IL-17i failures.
  4. IL-23 inhibitors — effective in psoriatic arthritis and psoriasis, but not in axial AS. Skip for AS.

Back to Table of Contents

4. TNF Inhibitors (TNFi) — First-Line Biologics

TNF inhibitors are the oldest, best-studied, and usually the first biologic class offered for AS. They work in about two-thirds of patients.

Adalimumab (Humira)

40 mg subcutaneous every 2 weeks. The most prescribed biologic in the world. Self-injected at home as either a pre-filled pen (Humira Pen) or syringe. Refrigerated shipping, shelf-stable at room temperature for up to 14 days.

Etanercept (Enbrel)

50 mg subcutaneous weekly. Self-injected. Etanercept is a soluble TNF receptor fusion protein (slightly different mechanism from the monoclonal antibodies). Important caveat: etanercept is not effective for IBD, so avoid it in AS patients with concurrent Crohn’s or UC.

Infliximab (Remicade)

5 mg/kg IV infusion at weeks 0, 2, and 6, then every 6–8 weeks. Requires an infusion center — roughly a 2-hour appointment each time. No self-injection. Doses can be escalated in poor responders (up to 7.5–10 mg/kg or shortened intervals). Excellent evidence in AS + IBD and AS + uveitis.

Certolizumab pegol (Cimzia)

400 mg subcutaneous at weeks 0, 2, and 4, then 200 mg every 2 weeks or 400 mg every 4 weeks. Certolizumab is pegylated and lacks the Fc portion of a normal antibody — which means it does not actively cross the placenta. This makes it the safest TNFi in pregnancy. See Pregnancy and AS.

Golimumab (Simponi, Simponi Aria)

50 mg subcutaneous monthly (Simponi), or IV 2 mg/kg at weeks 0 and 4, then every 8 weeks (Simponi Aria). Monthly dosing is a selling point for patients who hate weekly or bi-weekly injections.

Biosimilars for TNFi

Biosimilars are FDA-approved, near-identical copies of the originator biologic — comparable to generic drugs for small molecules, although the regulatory pathway is different.

Biosimilars are often cheaper and have equivalent efficacy in head-to-head studies. Insurance companies may force a switch to whichever biosimilar they contract with this year — this is annoying but usually clinically fine.

TNFi Response and Structural Effects

60–70% of AS patients achieve a BASDAI 50 response (50% improvement in disease activity score) by week 12. Long-term studies show slower spinal fusion with sustained TNFi use, especially when started before significant syndesmophyte formation.

Back to Table of Contents

5. IL-17 Inhibitors (IL-17i) — When TNFi Fails or for Specific Comorbidities

IL-17 is a cytokine central to the spondyloarthritis disease process. Blocking it works well in AS and psoriasis, and somewhat less well in IBD (where it can actually cause trouble).

Secukinumab (Cosentyx)

150 mg or 300 mg subcutaneous weekly for 5 loading doses, then monthly. The 300 mg dose is typically used when psoriasis coexists.

Ixekizumab (Taltz)

80 mg subcutaneous at weeks 0, 2, 4, 6, 8, 10, and 12, then every 4 weeks. Aggressive loading front-loads the response.

Bimekizumab (Bimzelx)

Newer. Targets both IL-17A and IL-17F (where secukinumab and ixekizumab only target IL-17A). 160 mg subcutaneous with loading and maintenance schedules per label. Early data suggest higher response rates than single-target IL-17i.

When to Prefer IL-17i Over TNFi

IL-17i CAUTION in IBD

This is crucial. Secukinumab and ixekizumab can trigger or worsen Crohn’s disease and ulcerative colitis flares. If you have AS plus any form of IBD, choose a TNFi (adalimumab or infliximab) instead. See AS and IBD Overlap.

IL-17i Side Effects

Most characteristic: increased rate of candidiasis (oral thrush, vaginal yeast infections). Also injection site reactions and upper respiratory infections. Typically manageable, but tell your rheumatologist at the first sign of recurrent yeast.

Back to Table of Contents

6. JAK Inhibitors (JAKi) — Oral Option

JAK inhibitors are small molecules, not biologics in the strict sense, but they occupy the same therapeutic niche and are often grouped with biologics in clinical conversation.

Tofacitinib (Xeljanz)

5 mg twice daily. FDA approved for AS in 2021.

Upadacitinib (Rinvoq)

15 mg once daily. FDA approved for AS. Many rheumatologists prefer upadacitinib for its once-daily dosing and slightly more selective JAK1 inhibition.

Advantages of JAKi

Disadvantages of JAKi

The FDA has placed a boxed warning on all oral JAKi for MACE (major adverse cardiovascular events), malignancy, thrombosis, and serious infections. The warning is based on the ORAL-SURVEILLANCE trial, which was conducted in rheumatoid arthritis patients over age 50 with at least one cardiovascular risk factor. Whether the same risk applies to younger AS patients is debated, but the warning stands.

A baseline cardiovascular risk assessment is essential before starting a JAKi. They are usually reserved for patients who have failed at least one TNFi and one IL-17i, or who genuinely cannot do injections.

Cost and Monitoring

JAKi require quarterly lab monitoring: CBC, LFTs, and lipid panel. JAK inhibitors reliably raise LDL cholesterol and occasionally suppress neutrophil or lymphocyte counts.

Back to Table of Contents

7. IL-23 Inhibitors — Currently NOT Effective for AS

Ustekinumab (Stelara) and risankizumab (Skyrizi) block IL-23, a cytokine upstream of IL-17 in the inflammatory cascade. They work beautifully in psoriasis and, to a lesser degree, peripheral psoriatic arthritis. Randomized trials in ankylosing spondylitis showed no efficacy for axial disease. This was a genuine surprise to the field given the mechanistic logic.

If a provider suggests ustekinumab or risankizumab for your AS, push back. These drugs are appropriate for psoriatic arthritis with peripheral joint disease, not axial spondyloarthritis.

Back to Table of Contents

8. Picking Your Biologic — Decision Matrix

Use your comorbidities to pick the drug:

Back to Table of Contents

9. Cost and Insurance Reality

Brace yourself. These drugs are expensive.

Insurance coverage is usually available with prior authorization. The PA packet typically requires: documented NSAID failure (2+ NSAIDs for 2–4 weeks each), a BASDAI score, CRP or ESR results, and in some cases imaging. If your rheumatologist’s office does not help with this, ask specifically for their PA coordinator.

Manufacturer copay assistance programs dramatically reduce out-of-pocket costs for commercially-insured patients:

Patient assistance programs provide free drug to uninsured patients meeting income criteria — typically up to 400–500% of the federal poverty level. Apply directly through the manufacturer.

Specialty pharmacy is mandatory for most biologics — Accredo, CVS Specialty, and Walgreens Specialty are the big three. Retail pharmacies generally cannot fill these drugs. Expect monthly phone calls to confirm each shipment.

Switching biologics: insurance often enforces step therapy — you must fail a cheaper TNFi before they will pay for an IL-17i or JAKi. Document failures carefully so appeals go smoothly.

Back to Table of Contents

10. How to Give Yourself an Injection

If you have never given yourself a shot, the first one is nerve-wracking. After three or four, it’s boring. Tips that matter:

Back to Table of Contents

11. What to Expect — Timeline of Response

Back to Table of Contents

12. Side Effects — What to Watch

Common and usually manageable:

Serious but rare:

Cancer risk: TNFi use is associated with a slightly increased risk of lymphoma — roughly a doubling of baseline risk, but because baseline risk is very low the absolute numbers remain small. Non-melanoma skin cancers are more common; annual skin checks recommended.

Vaccines:

Back to Table of Contents

13. Pre-Treatment Screening Checklist

Before the first dose:

Back to Table of Contents

14. Monitoring During Treatment

Back to Table of Contents

15. Stopping or Switching

Never stop a biologic cold-turkey. Work with your rheumatologist to taper or bridge. Biologics can be paused for surgery — typically one dosing interval before and held until wounds are healed, often 1–2 weeks post-op — with low risk of losing response. Longer pauses (months) can cause loss of response that may require re-titration or a switch.

Switching within a class is common and often works: Humira to Cimzia, Cosentyx to Taltz. Switching across classes (TNFi to IL-17i, IL-17i to JAKi) is the standard move after primary or secondary failure.

Back to Table of Contents

16. Combining Biologics with Other Drugs

For non-pharmacologic adjuncts, see Exercise and PT Protocol — exercise remains foundational no matter which biologic you’re on.

Back to Table of Contents

17. Key Research Papers

  1. van der Heijde D, et al. 2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis. Annals of the Rheumatic Diseases. 2017.
  2. Ward MM, et al. 2019 Update of the ACR/SAA/SPARTAN recommendations for the treatment of axial spondyloarthritis. Arthritis & Rheumatology. 2019.
  3. Baeten D, et al. Secukinumab, an interleukin-17A inhibitor, in ankylosing spondylitis (MEASURE 1 and MEASURE 2). New England Journal of Medicine. 2015.
  4. van der Heijde D, et al. Ixekizumab, an interleukin-17A antagonist in radiographic axial spondyloarthritis (COAST-V). Lancet. 2018.

Back to Table of Contents

18. Research Papers

Curated PubMed topic searches — each link opens a live query so you always see the most recent literature.

  1. PubMed: Ankylosing spondylitis biologic therapy
  2. PubMed: TNF inhibitor ankylosing spondylitis
  3. PubMed: Secukinumab ankylosing spondylitis
  4. PubMed: Ixekizumab axial spondyloarthritis
  5. PubMed: Tofacitinib ankylosing spondylitis
  6. PubMed: Upadacitinib ankylosing spondylitis
  7. PubMed: Biosimilar spondyloarthritis

Back to Table of Contents

Connections

Back to Table of Contents